Patents Examined by Julie Ha
  • C3 fusion protein and methods of making and using thereof
    Patent number: 11324802
    Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 10, 2022
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
  • Peptides and analogs for use in the treatment of oral mucositis
    Patent number: 11311598
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 26, 2022
    Assignee: Soligenix, Inc.
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Sunflower seed protein-derived peptides
    Patent number: 11312754
    Abstract: A protein hydrolysate composition is provided. The protein hydrolysate composition comprises isolated peptides useful for ameliorating a condition of a subject. Compositions comprising the protein hydrolysate composition are also provided. The compositions may be adapted for oral or topical administration to the subject, and may compose a foodstuff or beverage (e.g. a medical food), a topical composition (e.g. a lotion, cream, etc.), a kit, and the like. A methods of ameliorating the condition of the subject is further provided. The method include administering the protein hydrolysate composition to the subject. The method may be useful in reducing blood pressure, inflammation, reduced immunity, and/or oxidative stress in the subject.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC
    Inventors: Rodney A. Velliquette, Eugene Maly
  • Cell hydrolysate composition from cultivated cells and applications thereof
    Patent number: 11306342
    Abstract: A cell hydrolysate composition, the composition comprising substantially all protein polypeptides and/or polypeptide fragments derived substantially from all the proteins in a cell from an in vitro cell culture.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: April 19, 2022
    Assignee: Avant Meats Company Limited
    Inventors: Po San Mario Chin, Kai Yi Carrie Chan, Chun Hei Poon
  • Therapeutic agent for inflammatory bowel disease
    Patent number: 11298403
    Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing weight loss and an effect of suppressing shortening of the large intestine and mucosal damage in an animal model of inflammatory bowel diseases. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of inflammatory bowel diseases, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: April 12, 2022
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takashi Shimbo, Takehiko Yamazaki
  • Agent for inhibiting or reducing light sensitivity
    Patent number: 11298396
    Abstract: Disclosed is an agent for inhibiting or reducing light sensitivity comprising a substance that inhibits or reduces ubiquitination, for example, an agent for inhibiting or reducing light sensitivity capable of protecting a retina, reducing retinal degeneration, reducing aging of a retina and/or reducing hyperesthesia. The present invention is suitable for use in amelioration or prevention of a symptom associated with light reception, such as age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy, diabetic retinopathy, macular edema, retinal ischemia, photosensitive seizure, photosensitive epilepsy, psychiatric disorders, photic maculopathy, asthenopia, retinal dysfunction, sleep disorders, migraine and light-induced damage.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: April 12, 2022
    Assignee: Osaka University
    Inventor: Takahisa Furukawa
  • Protection and delivery of multiple therapeutic proteins
    Patent number: 11298423
    Abstract: Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1? embedded in the hydrogel, which is useful in treating a myocardial infarction.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 12, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Eric M. Jeffries, Noah R. Johnson, Daniel Long, Yadong Wang
  • Use of gaboxadol in the treatment of diabetes and related conditions
    Patent number: 11291658
    Abstract: Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease. In embodiments, administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. Gaboxadol or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: April 5, 2022
    Assignee: Ovid Therapeutics Inc.
    Inventor: Matthew During
  • Highly absorbable oral tyrosine formulation
    Patent number: 11278586
    Abstract: Provided is a tyrosine formulation excellent in bioabsorbability of tyrosine when ingested orally. An oral formulation with improved bioabsorbability of tyrosine, including glycyltyrosine or a salt thereof or a solvate thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 22, 2022
    Assignee: Kao Corporation
    Inventors: Kotaro Tamura, Masazumi Iwashita, Yoshihiko Minegishi
  • Dummy-fluorescent protein fusions and methods of use
    Patent number: 11278633
    Abstract: The invention, in some aspects, relates to dummy-fluorescent (DF) polypeptide molecules and their encoding nucleic acid molecules and use of such molecules in fusion proteins and their encoding nucleic acid molecules. Compositions of the invention may be delivered to cells and subjects and used in methods to modulate electrical activity of cells in which they are expressed, and for treatment of diseases and conditions in subjects.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 22, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Aimei Yang, Demian Park, Kiryl Piatkevich, Edward Boyden
  • Antimicrobial adhesive protein, antimicrobial nanoparticle, antimicrobial composition comprising same nanoparticle, and preparation method for same composition
    Patent number: 11267851
    Abstract: An antimicrobial adhesive protein, an antimicrobial nanoparticle, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described and, more particularly, an antimicrobial adhesive protein in which an antibiotic peptide is linked to a mussel adhesive protein, a mussel adhesive protein derivative of which a tyrosine residue within the antimicrobial adhesive protein is modified with a catechol derivative, an antimicrobial nanoparticle including a metal capable of forming a coordinate bond with a derivative of the mussel adhesive protein and having intrinsic antimicrobial activity, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: March 8, 2022
    Assignees: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Hyung Joon Cha, Yun Kee Jo, Yeonsu Jeong
  • Angio-3 for treatment of retinal angiogenic diseases
    Patent number: 11266710
    Abstract: This disclosure provides methods of a method of treating a retinal angiogenic in a subject comprising administering an effective amount of an Angio-3 peptide.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 8, 2022
    Assignee: Singapore Health Services Pte Ltd.
    Inventors: Michael Belkin, Veluchamy Amutha Barathi, Rajamani Lakshminarayanan, R. Manjunatha Kini, Ge Ruowen, Tien Yin Wong, Gemmy Chui Ming Cheung
  • Methods for the regulation of matrix metalloproteinase expression
    Patent number: 11266709
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: March 8, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Transdermal peptide with nuclear localization ability and use thereof
    Patent number: 11261222
    Abstract: A transdermal peptide with a nuclear localization ability and having an amino acid sequence as shown in SEQ ID NO: 1 is disclosed. A fusion protein including a macromolecular protein with one end being linked to the transdermal peptide is also disclosed. The transdermal peptide can be used in the preparation of a medicament or a transdermal preparation for treating skin diseases. A medicament for treating a skin disease includes the transdermal peptide and a pharmaceutically acceptable excipient. The transdermal peptide enters the cells autonomously to locate in the nuclei, and can penetrate through the stratum corneum of the skin into cells in the dermis. The peptide is conveniently synthesized artificially and suitable for transdermal administration, and has a therapeutic potential via transdermal administration by carrying a drug for treating skin diseases.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: March 1, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Shuyu Zhang, Jianping Cao, Daojiang Yu, Wei Zhu
  • Glucagon derivative and a composition comprising a long acting conjugate of the same
    Patent number: 11261227
    Abstract: A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: March 1, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Conjugate of methotrexate and peptide
    Patent number: 11253604
    Abstract: The present invention relates to a compound having a structure in which methotrexate and a peptide are connected via a covalent bond, and an anticancer or anti-inflammatory pharmaceutical composition comprising same. The compound having a structure in which methotrexate and a peptide are connected via a covalent bond of the present invention has excellent biological activity such as anticancer or anti-inflammatory action and has markedly reduced toxicity with respect to cells, and thus, may be usefully used in various fields such as medicine and medical supplies.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 22, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim, Seon Soo Kim
  • Cyclic peptide analogs and conjugates thereof
    Patent number: 11254705
    Abstract: Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: February 22, 2022
    Assignee: SIRENAS LLC
    Inventors: Ippei Usui, Bryan Junn Lee, Steven Bruce Cohen, Venkat Rami Reddy Macherla, Jacob Neal Beverage, Chung-Mao Pan, Farhana Barmare, Eduardo Esquenazi
  • S100A8/S100A9-induced immunotolerance in newborn subjects
    Patent number: 11253570
    Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-?B-associated postnatal inflammatory disorder.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: February 22, 2022
    Assignees: Medizinische Hochschule Hannover (MHH), Westfalische Wilhelms-Universität Münster
    Inventors: Dorothee Viemann, Johannes Roth, Thomas Vogl
  • Methods of treating multifocal cancer
    Patent number: 11231421
    Abstract: The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 25, 2022
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Anthelmintic depsipeptide compounds
    Patent number: 11230571
    Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: January 25, 2022
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Q. Meng, Hyoung Ik Lee